Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches

Drug Metabolism and Drug Interactions

Volumn 19, Issue 1, 2002, Pages 49-64

  Mahmood, Iftekhar ^a  

^a Center for Biologics Evaluation/Res   (United States)

Author keywords

Allometric scaling; Clearance; In vitro scaling; Rule of exponents

Indexed keywords

CITALOPRAM; CYCLOPHOSPHAMIDE; DIAZEPAM; DOFETILIDE; ETHINYLESTRADIOL; METOPROLOL; PROPAFENONE; PROPRANOLOL; QUINIDINE; SILDENAFIL; TACROLIMUS; THEOPHYLLINE; TIRILAZAD; TOLCAPONE; TROGLITAZONE; WARFARIN;

ALLOMETRY; BODY WEIGHT; BRAIN WEIGHT; COMPARATIVE STUDY; CONFERENCE PAPER; DRUG CLEARANCE; HUMAN; LIFESPAN; LIVER CLEARANCE; LIVER MICROSOME; PREDICTION; RELIABILITY;

EID: 0036379076     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2002.19.1.49     Document Type: Conference Paper

References (49)

1. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973; 1: 435-461.
2. Mahmood I, Balian JD. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 1996; 85: 411-414.
3. Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 1996; 26: 887-895.
4. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15: 1071-1121.
5. Boxenbaum H, Fertig JB. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 1984; 9: 177-183.
6. Lave TH, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo PH. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 1997; 86: 584-590.
7. Obach RS, Baxter JG, Liston TE, Silber BM, Jones C, Macintyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism. J Pharmacol Exp Ther 1997; 283: 46-58.
8. Mahmood I. Integration of in-vitro data and brain weight in allometric scaling to predict clearance in humans: some suggestions. J Pharm Sci 1998; 87: 527-529.
9. Smith DA, Abel SM, Hyland R, Jones BC. Human cytochrome P450: selectivity and measurement in vivo. Xenobiotica 1998; 12: 1095-1128.
10. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73: 147-171.
11. Sacher G. Relation of lifespan to brain weight and body weight in mammals. In: C1BA Foundation Colloquia on Aging. Wolstenholme GEW, O'Connor M, eds. London: Churchill, 1959; 115-133.
12. Boxenbaum H, Dilea C. First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995; 35: 957-966.
13. Houston B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479.
14. Kato R, Yamazoe Y. The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 1994; 4: 359-362.
15. Klotz U, Antonin KH, Bieck PR. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther 1976; 199: 67-73.
16. Bachmann K. Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 1989; 9: 331-338.
17. Guentert TW, Huang JD, Qie S. Disposition of quinidine in the rabbit. J Pharm Sci 1982; 71: 812-815.
18. Iven H. The pharmacokinetics and organ distribution of ajmaline and quinidine in the mouse. Naunyn-Schmied Arch Pharmacol 1977; 298: 43-50.
19. Swada Y, Hanano M, Sugiyama Y, Iga T. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetics parameters in rats. J Pharmacokin Biopharm 1985; 13: 477-492.
20. Puigdemont A, Guitart R, Mora FD, Arboix, M. Prediction of the disposition of propafenone in humans and dogs from pharmacokinetic parameters in other animal species. J Pharm Sci 1992; 80: 1106-1109.
21. Dilger K, Greiner B, Fromm M, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics 1999; 9: 551-559.
22. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 1989; 45: 28-33.
23. Walker DK, Ackland, MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297-310.
24. Hyland R, Roe EGH, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001; 51: 239-248.
25. Rane A, Hogstedt S, Lindberg B, Regardh CG, Jorulf H. Comparison of different clearance estimates for metoprolol in the Rhesus monkey. J Pharmacol Exp Ther 1984; 228: 774-778.
26. Belpaire FM, Smet FD, Vynckier LJ, Vermeulen AM, Rosseel MT, Bogaert MG, Moachon-Chauvelot L. Effect of aging on the pharmacokinetics of metoprolol and propranolol in the rat. J Pharmacol Exp Ther 1990; 254: 116-122.
27. Murthy SS, Nelson WL, Shen DD, Power JM, Cahill CM, McClean AJ. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. Drug Metab Disp 1991; 19: 1093-1100.
28. Bortolotti A, Castelli D, Verotta D, Bonati M. Pharmacokinetic and pharmacodynamic modeling of metoprolol in rabbits with liver failure. Eur J Drug Metab Pharmacokinet 1989; 14: 145-151.
29. Kim M, Shen DD, Eddy CA, Nelson WL. Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. Drug Metab Disp 1993; 21: 309-317.
30. Gascon RA, Calvo B, Hernandez RM, Dominguez-Gil A, Pedraz J. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interaction. Pharm Res 1994; 11: 945-950.
31. Smith DA, Rasmussen HS, Stopher DA, Walker DK. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 1992; 22: 709-719.
32. Overo FK. Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuro-Psych Biol Psych 1982; 6: 297-309.
33. Olessen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999; 59: 298-309.
34. Evans GH, Nies AS, Shand DG. The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma protein binding in man, monkey, dog and rat. J Pharmacol Ther 1973; 186: 114-122.
35. Marathe PH, Shen DD, Nelson WL. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition. Drug Metab Disp 1994; 22: 237-247.
36. Chang KHT, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
37. Dusterberg B, Kuhne G, Tauber U. Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. Arzneim-Forsch 1986; 36: 1187-1190.
38. Purba HS, Maggs JL, Orme MLE, Back DJ, Park BK. The metabolism of 17α-ethinylestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol 1987; 23: 447-453.
39. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama, Y. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 1996; 277: 1630-1641.
40. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 1999; 37: 91-104.
41. 14C tirilazad mesylate to rabbit, dog, monkey and human. Pharm Res 1992; 9 (Suppl): S312.
42. Wienkers LC, Steenwyk RC, Sanders PE, Pearson PG. Biotransformation of tirilazad in humans: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 982-990.
43. Wienkers LC, Steenwyk RC, Hauer MJ, Fleishaker JC, Sanders PE, Pearson PG. Biotransformation of tirilazad in humans: 3. Tirilazad A-ring reduction by human liver microsomal 5α-reductase type 1 and type 2. J Pharmacol Exp Ther 1996; 287: 583-590.
44. Riekosezewski W, Chow FS, Jusko WJ. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. Drug Metab Disp 1993; 21: 690-698.
45. Takada K, Usuda H, Oh-hashi, M, Yoshikawa H. Muranishi S, Tanaka H. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administration to rats. J Pharmacobio-dyn 1991; 14: 34-42.
46. Venkataramanan R, Cadoff JE, Warty V, Iwasaki K., Nagase K, Krajack A, Imventarza O, Todo S, Fung J, Starzl TE. Pharmacokinetics of FK-506: preclinical and clinical studies. Transplant Prog 1990; 22 (Suppl 1): 52-56.
47. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckhart G, Starzl T. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-430.
48. Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, Shimada T, Funae Y. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 1994; 47: 727-735.
49. Mahmood I. Interspecies scaling: is a priori knowledge of cytochrome P450 isozymes involved in drug metabolism helpful in prediction of clearance in humans from animal data? Drug Metab Drug Interact 2001; 18: 135-147.